Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Pain 9Cancer Pain 5Head and Neck Neoplasms 3Colonic Neoplasms 3Agnosia 3Rectal Neoplasms 2Chronic Pain 2Breakthrough Pain 2post laminectomy syndrome 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Terminal Cancer 1Prostatic Neoplasms 1Postoperative Cognitive Complications 1Polyps 1Pleural Effusion, Malignant 1Patient Satisfaction 1Pain, Postoperative 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Ileus 1Failed Back Surgery Syndrome 1Emergencies 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1Constipation 1Arrhythmias, Cardiac 1

Interventions

Fentanyl 2Ultracet 1Morphine 1Gastrostomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Breakthrough Pain × Fentanyl × Clear all
NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed
20 enrolled
Head & Neck

Head and Neck Neoplasms, Breakthrough Pain

NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡